Taizhou promotes new highland for pharmaceutical industry development

Taizhou City of East China’s Jiangsu Province has taken the lead in the high-quality development under the guidance of new ideas and new concepts so as to accelerate the construction of the health industry cluster with excellent industrial layout, high agglomeration degree and strong innovation ability.

In early June, the monkeypox nucleic acid detection reagent developed by a Taizhou-based pharmaceutical company obtained the EU safety certification. The first batch of 100,000 reagents have been sent to Europe, which will help many countries and regions fight against the monkeypox epidemic.

Yuan Jianhua, Deputy General Manager of Jiangsu Mole Biotechnology Co., Ltd.

Pharmaceutical companies in Taizhou have continued to consolidate their leading advantages in the pharmaceutical industry by developing the world's first drug for port wine stains, the world's only drug for the treatment of mild to moderate Alzheimer's disease, and the first domestic drug to improve acute lung injury from new coronary pneumonia and the first genetic test reagent that can diagnose early-stage liver cancer.

Behind the surge of more than 2,100 innovative achievements is the high-quality development of the industry that Taizhou has taken the initiative to change, reform and innovate in the face of fierce competition on the new track.

Ye Donghua, Secretary of the Party Working Committee of Taizhou Pharmaceutical High-tech Zone, Secretary of the Gaogang District Committee

By gathering high-end talents, attracting high-end achievements, and developing high-end industries, Taizhou has made efforts in multiple directions, including park reform, platform construction, and talent gathering, to integrate the pharmaceutical high-tech zone and the Gaogang District into a "special zone", and optimize the pharmaceutical industry on a larger scale.

Taizhou has introduced innovative resources from the International Genetic Engineering and Biotechnology Center, Fudan University, and Peking University School of Medicine, with a view to improving the independent innovation capability of the pharmaceutical industry, investing 100 million yuan in special funds every year to support talent development, and introducing more than 4,200 high-level biomedical professionals and talents at home and abroad.

In the face of the adverse impact of the epidemic on the economy, Taizhou has introduced 15 measures to help pharmaceutical companies solve production and operation difficulties from financial benefits, burden reduction, and market development.

Leng Yuan, Head of Global Supply Greater China for Boehringer Ingelheim Animal Health

Taizhou has been approved as the country's only pilot for the development of a new vaccine industry, leading the country in the innovation and development of antibody drugs, forming a complete system of drug research and development, clinical transformation and industrialization.

Taizhou's biopharmaceutical and new medical device industries registered output value of more than 100 billion yuan, ranking first in prefecture-level cities across the country. From January to April, Taizhou reported 29.41 billion yuan, 29.45 billion yuan and 5.82 billion yuan in the output value, sales and profits of the pharmaceutical industry, a year-on-year increase of 12.3%, 17.3% and 47.1%.

Ding Zhiqiang, Director of Taizhou Development and Reform Commission